Literature DB >> 11120984

Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance.

D H Kwon1, M Lee, J J Kim, J G Kim, F A El-Zaatari, M S Osato, D Y Graham.   

Abstract

The prevalence of furazolidone, nitrofurantoin, and metronidazole resistance among Helicobacter pylori strains was assessed with 431 clinical isolates. Fifty-two percent were metronidazole resistant, compared to 2% (7 of 431) with resistance to furazolidone and nitrofurantoin. All seven furazolidone- and nitrofurantoin-resistant isolates were also metronidazole resistant. rdxA, frxA, and fdxB knockouts did not result in furazolidone or nitrofurantoin resistance. These data suggest that furazolidone and nitrofurantoin may be good alternatives to metronidazole for treating H. pylori infection.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11120984      PMCID： PMC90279          DOI： 10.1128/AAC.45.1.306-308.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Furazolidone combination therapies for Helicobacter pylori infection in the United States.

Authors:  D Y Graham; M S Osato; J Hoffman; A R Opekun; S Y Anderson; H M El-Zimaity
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

Review 2.  Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.

Authors:  D Y Graham; W A de Boer; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

Review 3.  The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?

Authors:  W A de Boer; G N Tytgat
Journal:  Scand J Gastroenterol       Date:  1995-05       Impact factor: 2.423

4.  Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States.

Authors:  M S Osato; R Reddy; D Y Graham
Journal:  Int J Antimicrob Agents       Date:  1999-08       Impact factor: 5.283

5.  Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori.

Authors:  D H Kwon; F A El-Zaatari; M Kato; M S Osato; R Reddy; Y Yamaoka; D Y Graham
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 6.  Helicobacter pylori.

Authors:  J Parsonnet
Journal:  Infect Dis Clin North Am       Date:  1998-03       Impact factor: 5.982

7.  Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori.

Authors:  P Kaihovaara; J Höök-Nikanne; M Uusi-Oukari; T U Kosunen; M Salaspuro
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

8.  Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase.

Authors:  A Goodwin; D Kersulyte; G Sisson; S J Veldhuyzen van Zanten; D E Berg; P S Hoffman
Journal:  Mol Microbiol       Date:  1998-04       Impact factor: 3.501

9.  Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates.

Authors:  M P Dore; M S Osato; D H Kwon; D Y Graham; F A el-Zaatari
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

10.  Helicobacter pylori porCDAB and oorDABC genes encode distinct pyruvate:flavodoxin and 2-oxoglutarate:acceptor oxidoreductases which mediate electron transport to NADP.

Authors:  N J Hughes; C L Clayton; P A Chalk; D J Kelly
Journal:  J Bacteriol       Date:  1998-03       Impact factor: 3.490
View more
  16 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance.

Authors:  Zhaoliang Su; Huaxi Xu; Chiyu Zhang; Shihe Shao; Liangju Li; Hua Wang; Huifang Wang; Gufeng Qiu
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

Review 3.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

4.  Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study.

Authors:  György M Buzás; Hajnalka Györffy; Ilona Széles; Anna Szentmihályi
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

Review 5.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

6.  Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.

Authors:  Guofei Dai; Ni Cheng; Lei Dong; Mutsumi Muramatsu; Shudong Xiao; Ming-Wei Wang; De-Xu Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

8.  Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

Authors:  Hong Cheng; Fu-Lian Hu
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

9.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

10.  Drug utilization of clarithromycin for gastrointestinal disease treatment.

Authors:  Quan Zhou; Ling-Ling Zhu; Xiao-Feng Yan; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.